Creditor Relations | Cheplapharm

Nachhaltig und wachstumsstark

Nachhaltigkeit und Wachstum sind die Eckpfeiler unserer Unternehmensstrategie. An dieser Philosophie haben wir auch unser diversifiziertes Finanzierungskonzept ausgerichtet und möchten für unsere Investor:innen ein zuverlässiger und beständiger Partner sein.

Vertrauensvoller Dialog

Finanzierungsstrategie

High Yield Bonds

CHEPLAPHARM Arzneimittel GmbH

EUR 725,000,000.00

10 May 2023

15 May 2030

Senior Secured

7.500%

15 May / 15 November - semi-annually

XS2618867159

A351TE

New York Law

High Yield Bonds

CHEPLAPHARM Arzneimittel GmbH

EUR 325,000,000.00

10 May 2023

15 May 2030

Senior Secured (Floating Rate)

3-month EURIBOR (0% Floor) + 4.75%

15 February / 15 May / 15 August / 15 November

XS2618840974

A351TF

New York Law

High Yield Bonds

CHEPLAPHARM Arzneimittel GmbH

USD 500,000,000.00

15 October 2020

15 January 2028

Senior Secured

5.500%

15 January / 15 July - semi-annually

USD1T29ZAB81

A3H2YN

New York Law

High Yield Bonds

CHEPLAPHARM Arzneimittel GmbH

EUR 500,000,000.00

11 February 2020

11 February 2027

Senior Secured

3.50%

15 February / 15 August - semi-annually

XS2112973107

A254SJ

New York Law

High Yield Bonds

CHEPLAPHARM Arzneimittel GmbH

EUR 575,000,000.00

15 October 2020

15 January 2028

Senior Secured

4.375%

15 January / 15 July - semi-annually

XS2243548273

A3H2YL

New York Law

Term Loan B

CHEPLAPHARM Arzneimittel GmbH

EUR 1,480,000,000.00

22 February 2022

21 February 2029

Senior Secured

EURIBOR (0%Floor) +4.00%

one, three or six months

English Law

Deutsche Bank Luxembourg S.A.

Investor Relations Themenbereiche

Ratings

chevron_right

ESG Information

chevron_right

IR Kontakt & Events

chevron_right